Canary Speech Revolutionizing Disease Detection with Vocal Biomarkers

Description

“We analyze vocal biomarkers in near real time and correlate that to a clinical diagnosis and create an algorithm that then can independently identify a range of different diseases in the human voice during conversation,” Henry O’Connell, CEO and Co-founder of Canary Speech, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O’Connell joins BI analyst Jonathan Palmer to discuss the company’s origins, its unique approach to vocal analysis using over 2,500 speech features and its commitment to clinical validation through partnerships with leading healthcare institutions. The conversation touches on Canary’s foundational team, extensive patent portfolio and platform approach that enables the development of models for a wide range of diseases.